



NEWS RELEASE

CareDx Announces Appointment of George W Bickerstaff to its Board of Directors

Brisbane, CA, April 25, 2014, CareDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced the appointment of George Bickerstaff as a member of the Board of Directors effective immediately.

Bickerstaff is currently a Managing Director with M.M. Dillon & Co (previously known as CRT Investment Banking) and has held various roles with the company since 2005. M.M. Dillon & Co specializes in advising capital structure and other strategies for public and privately held companies. Prior to joining CRT Capital Group, Bickerstaff was Chief Financial Officer of Novartis Pharma AG located in Basel, Switzerland.

He has been instrumental in establishing the strategic, operating and financial direction of numerous private and public companies. During his career, Bickerstaff has provided financial leadership for mergers and acquisitions and has funded and operated various venture capital businesses.

He has a broad range of operating and finance experiences. After receiving engineering and business degrees, he started his career at General Electric in manufacturing and then moved into finance. He subsequently joined The Dun & Bradstreet Corporation where he held various senior finance positions including Chief Financial Officer of IMS Health, the largest global publicly traded healthcare information services provider.

Bickerstaff has been on the board of directors and board of trustees of more than a dozen international private and public companies and philanthropic organizations. He has been a guest speaker on global finance at various international industry associations and graduate business schools, including Harvard Business School. He has lived and worked in five countries on four continents.

"We are very pleased to welcome George to the CareDx Board of Director's team. He is joining at a pivotal point in our evolution as we grow our molecular diagnostics platform," said Peter Maag, President and Chief Executive Officer of CareDx, Inc.

About AlloMap®

AlloMap MolecularTesting is a non-invasive gene expression test used to aid in the identification of heart transplant recipients who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive gene-expression test and surveillance solutions for transplant recipients. The company commercializes AlloMap, which aids clinicians in identifying heart transplant recipients with stable graft function.

For more information, please visit: www.CareDxInc.com.

Contacts

Company

Bradley P. Sherrill
Senior Director, Marketing
Tel: 415-287-2397
bsherrill@CareDxInc.com